![](https://news.europawire.eu/wp-content/uploads/2013/10/AstraZeneca-144x150.jpg)
Phase II/III trial of AZD3293, an oral potent small molecule inhibitor of BACE, aims to enrol more than 1,500 patients in 15 countries LONDON, 2-12-2014 — /EuropaWire/ — AstraZeneca and Eli Lilly and Company (Lilly) today announced enrolment of the … Read the full press release